AnaptysBio Inc (ANAB)
25.02
+0.22
(+0.89%)
USD |
NASDAQ |
Jun 28, 16:00
25.02
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Research and Development Expense (Annual): 132.28M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 132.28M |
| December 31, 2022 | 88.80M |
| December 31, 2021 | 98.50M |
| December 31, 2020 | 80.02M |
| December 31, 2019 | 99.34M |
| December 31, 2018 | 56.20M |
| Date | Value |
|---|---|
| December 31, 2017 | 29.44M |
| December 31, 2016 | 15.42M |
| December 31, 2015 | 17.30M |
| December 31, 2014 | 8.614M |
| December 31, 2013 | 8.82M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
80.02M
Minimum
2020
132.28M
Maximum
2023
99.79M
Average
98.50M
Median
2021
Research and Development Expense (Annual) Benchmarks
| XOMA Corp | 0.143M |
| Fate Therapeutics Inc | 172.60M |
| Ocular Therapeutix Inc | 61.06M |
| Apellis Pharmaceuticals Inc | 354.39M |
| Sutro Biopharma Inc | 180.42M |